Last reviewed 2026-04-20 · How we verify

PF-07321332/ritonavir (pf-07321332-ritonavir)

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Dysgeusia
• Diarrhoea
• Fibrin D dimer increased
• Headache
• COVID-19
• Nausea
• Upper respiratory tract infection
• Activated partial thromboplastin time prolonged
• Alanine aminotransferase increased
• Cough
• Blood thyroid stimulating hormone increased
• Nasopharyngitis

Key clinical trials

• A Study to Learn How Paxlovid [Nirmatrelvir-ritonavir/PF-07321332] Works in COVID-19 Patients Who Are Elderly or Have Medical Conditions.
• A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19 (PHASE1)
• EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease (PHASE3)
• EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19 (PHASE2, PHASE3)
• Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation (PHASE1)
• A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who Are Healthy Volunteers Co-administered the Medicine Rosuvastatin (PHASE1)
• A Study to Learn About the Study Medicine PF-07321332 and Ritonavir in Adult Healthy Chinese Participants. (PHASE1)
• A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• PF-07321332/ritonavir CI brief — competitive landscape report
• PF-07321332/ritonavir updates RSS · CI watch RSS
• Pfizer Inc. portfolio CI